Jin, Haojie

circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity

Li, B., Zhu, L., Lu, C., Wang, C., Wang, H., Jin, H., Ma, X., Cheng, Z., Yu, C., Wang, S., et al. (2021) · Nature Communications

Circular RNAs in diseasesCancer-related molecular mechanisms research

Cited by 697

Rational combinations of targeted cancer therapies: background, advances and challenges

Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 503

Inducing and exploiting vulnerabilities for the treatment of liver cancer

Wang, C., Vegna, S., Jin, H., Benedict, B., Lieftink, C., Ramirez, C., de Oliveira, R. L., Morris, B., Gadiot, J., Wang, W., et al. (2019) · Nature

Telomeres, Telomerase, and SenescenceHepatocellular Carcinoma Treatment and Prognosis

Cited by 427

The Cancer SENESCopedia: A delineation of cancer cell senescence

Jochems, F., Thijssen, B., De Conti, G., Jansen, R., Pogacar, Z., Groot, K., Wang, L., Schepers, A., Wang, C., Jin, H., et al. (2021) · Cell Reports

Telomeres, Telomerase, and SenescenceGenetics, Aging, and Longevity in Model Organisms

Cited by 201

CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma

Wang, C., Wang, H., Lieftink, C., du Chatinier, A., Gao, D., Jin, G., Jin, H., Beijersbergen, R. L., Qin, W., & Bernards, R. (2020) · Gut

Hepatocellular Carcinoma Treatment and PrognosisCancer-related Molecular Pathways

Cited by 107